论文部分内容阅读
背景与目的:90K是一种分泌性糖蛋白,在一些肿瘤患者中,肿瘤组织90K表达与预后相关,非霍奇金淋巴瘤肿瘤组织90K表达和预后的关系尚未见报道。本研究检测90K在初治非霍奇金淋巴瘤肿瘤组织中的表达水平,并探讨其临床意义。方法:采用免疫组化的方法检测90K在110例非霍奇金淋巴瘤肿瘤组织中的表达,回顾性分析90K表达与CHOP方案的近期疗效和远期生存的关系。结果:110例非霍奇金淋巴瘤中,90K阴性36例,弱阳性27例,较强阳性17例,强阳性30例,阳性率67.3%(74/110),其表达与性别、年龄、IPI以及临床病理特征等均无相关性(P>0.05)。109例初治患者采用标准CHOP方案化疗,90K高表达组(较强阳性和强阳性)CHOP方案化疗的近期有效(CR+PR)率65.2%(30/46)低于低表达组(阴性和弱阳性)的有效率82.5%(52/63),差异有显著性(P=0.039),但90K表达和远期生存无相关性(P>0.05)。结论:90K在非霍奇金淋巴瘤肿瘤组织中的表达对预测CHOP方案的近期疗效有一定临床价值,能否成为预测非霍奇金淋巴瘤预后的肿瘤标志物还有待进一步研究。
BACKGROUND & OBJECTIVE: 90K is a secreted glycoprotein. In some tumor patients, the expression of 90K is correlated with prognosis. The relationship between 90K expression and prognosis in non-Hodgkin’s lymphoma has not been reported yet. This study was to examine the expression of 90K in untreated non-Hodgkin’s lymphoma and explore its clinical significance. Methods: Immunohistochemical method was used to detect the expression of 90K in 110 cases of non-Hodgkin’s lymphoma. The relationship between 90K expression and CHOP regimen’s long-term survival was retrospectively analyzed. Results: In 110 cases of non-Hodgkin’s lymphoma, 90 cases were negative, 36 cases were weak, 27 cases were weak positive, 17 cases were strong positive, 30 cases were strong positive, the positive rate was 67.3% (74/110) IPI and clinicopathological features were not related (P> 0.05). Among the 109 newly diagnosed patients, the CHOP chemotherapy was the most effective and the rate of CR + PR of the CHOP regimen (90.2% vs 65.2%, 30/46) was lower than that of the low expression group (negative and Weak positive) was 82.5% (52/63), the difference was significant (P = 0.039), but there was no correlation between 90K expression and long-term survival (P> 0.05). Conclusion: The expression of 90K in non-Hodgkin’s lymphoma has some clinical value in predicting the curative effect of CHOP. Whether it can become a tumor marker to predict the prognosis of non-Hodgkin’s lymphoma remains to be further studied.